New Drug Gives Young Thyroid Cancer Patient a Second Chance at Life
https://www.verywellhealth.com/ret-inhibitor-drug-thyroid-cancer-5093500
WEBJan 9, 2021 · The FDA approved pralsetinib ( Gavreto ), a selective RET-inhibitor drug, for RET fusion-positive non-small cell lung cancers (NSCLC) on September 4, 2020, and RET-altered thyroid cancers on December 1, 2020. This medication, and others like it, provide a more targeted treatment option for patients with these diagnoses.
DA: 92 PA: 35 MOZ Rank: 8